

Revised Draft Agenda
Biocides Working Group Meeting I-2022
28 March – 8 April 2022
Additional dates for ENV WG: 21 March, 12 April

WG-I-2022 meetings are held as virtual meetings via WebEx

The time is indicated in Helsinki time.

Tuesday 29 March	10:00-18:00	APCP WG
Wednesday 30 March	10:00-18:00	APCP WG
Thursday 31 March	10:00-18:00	APCP WG
Friday 01 April	10:00-18:00	APCP WG
Thursday 31 March	10:00-18:00	TOX WG
Friday 01 April	10:00-18:00	TOX WG
Wednesday 6 April	10:30-18:00	TOX WG
Thursday 7 April	10:00-18:00	TOX WG
Friday 8 April	10:00-17:00	TOX WG
Monday 28 March	10:30-18:00	EFF WG
Wednesday 30 March	10:30-18:00	EFF WG
<i>Monday 21 March</i>	<i>13:00-18:00</i>	<i>ENV WG (item 7.11)</i>
Monday 4 April	13:00-17:00	ENV WG
Tuesday 5 April	10:00-17:00	ENV WG
Thursday 7 April	10:00-17:00	ENV WG
Friday 8 April	10:00-17:00	ENV WG

<i>Tuesday 12 April</i>	<i>10:00-16:00</i>	<i>EG on fate models</i>
-------------------------	--------------------	--------------------------

Analytical methods and physico-chemical properties Working Group		
Chair: Bernhard Krebs		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement on the minutes of WG IV 2021		<i>For agreement</i>
Item 6 - Discussion on Active Substances		eCA
6.1	Formic Acid PT 02, 03, 04, 05, 06 Meeting document: <i>WG I 2022_APCP_6-1</i>	BE <i>For agreement</i>
Item 7 - Discussions on Union Authorisations		eCA
7.1	UA for a product family containing L-(+)-lactic acid PT 03, 04 (BC-XR051157-11) Meeting document: <i>WG I 2022_APCP_7-1</i>	SI <i>For agreement</i>
7.2	UA for a product family containing L-(+)-lactic acid PT 02, 03, 04 (BC-HC051278-51) Meeting document: <i>WG I 2022_APCP_7-2</i>	FR <i>For agreement</i>
7.3	UA for a product containing 3-iodo-2-propynylbutylcarbamate (IPBC) PT 08 (BC-QN044827-14) Meeting document: <i>WG I 2022_APCP_7-3</i>	DK <i>For agreement</i>
7.4	UA for a product family containing Peracetic acid PT 02, 03, 04 (BC-EW057176-14) Meeting document: <i>WG I 2022_APCP_7-4</i>	BE <i>For agreement</i>

7.5	UA for a product family containing Chlorocresol PT 02, 03 (BC-RF039183-42) Meeting document: <i>WG I 2022_APCP_7-5</i> <i>For agreement</i>	FR
7.6	UA for a product family containing Hydrogen peroxide PT 02 (BC-MS029571-20) Meeting document: <i>WG I 2022_APCP_7-6</i> <i>For agreement</i>	DE
7.7	UA for a product family containing Hydrogen peroxide PT 02, 04 (BC-UE029056-42) Meeting document: <i>WG I 2022_APCP_7-7</i> <i>For agreement</i>	NL
7.8	UA for a product containing active chlorine released from chlorine PT 02, 05 (BC-EQ047299-18) Meeting document: <i>WG I 2022_APCP_7-8</i> <i>For agreement</i>	SI
7.9	UA for a product containing calcium dihydroxide/calcium hydroxide/caustic lime/hydrated lime/slaked lime PT 02, 03 (BC-JR038510-32) Meeting document: <i>WG I 2022_APCP_7-9</i> <i>For agreement</i>	FR
7.10	UA for a product containing calcium oxide/lime/burnt lime/quicklime PT 02, 03 (BC-VJ038509-19) Meeting document: <i>WG I 2022_APCP_7-10</i> <i>For agreement</i>	FR
Item 8 – AoB		

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-IV-2021		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Formic Acid PT 2-6 Meeting document: <i>WGI2022_TOX_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	BE
6.2	Reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2) (former MBO) PT 2, 6, 11,12,13 (ED ONLY) Meeting document: <i>WGI2022_TOX_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	AT
6.3	Reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 1:1)" (former HPT) PT 2, 6, 11, 13 (ED ONLY) Meeting document: <i>WGI2022_TOX_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	AT

Item 7 - Discussion of Union Authorisations		eCA
7.1	<p>UA for a product containing active chlorine released from chlorine PT 2, 5 (BC-EQ047299-18) Meeting document: <i>WGI2022_TOX_7-1</i></p> <p style="text-align: right;"><i>For agreement</i></p>	SI
7.2	<p>UA for a product containing calcium dihydroxide/calcium hydroxide/caustic lime/hydrated lime/slaked lime PT 2, 3 (BC-JR038510-32) Meeting document: <i>WGI2022_TOX_7-2</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FR
7.3	<p>UA for a product containing calcium oxide/lime/burnt lime/quicklime PT 2, 3 (BC-VJ038509-19) Meeting document: <i>WGI2022_TOX_7-3</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FR
7.4	<p>UA for a product family containing Peracetic acid PT 2, 3, 4 (BC-EW057176-14) Meeting document: <i>WGI2022_TOX_7-4</i></p> <p style="text-align: right;"><i>For agreement</i></p>	BE
7.5	<p>UA for a product family containing Hydrogen peroxide PT 2 (BC-MS029571-20) Meeting document: <i>WGI2022_TOX_7-5</i></p> <p style="text-align: right;"><i>For agreement</i></p>	DE
7.6	<p>UA for a product family containing Hydrogen peroxide PT 2, 4 (BC-UE029056-42) Meeting document: <i>WGI2022_TOX_7-6</i></p> <p style="text-align: right;"><i>For agreement</i></p>	NL
7.7	<p>UA for a product family containing L-(+)-lactic acid PT 3, 4 (BC-XR051157-11) Meeting document: <i>WGI2022_TOX_7-7</i></p> <p style="text-align: right;"><i>For agreement</i></p>	SI

7.8	UA for a product containing 3-iodo-2-propynylbutylcarbamate (IPBC) PT 8 (BC-QN044827-14) Meeting document: <i>WGI2022_TOX_7-8</i> <i>For agreement</i>	DK
7.9	UA for a product family containing L-(+)-lactic acid PT 2, 3, 4 (BC-HC051278-51) Meeting document: <i>WGI2022_TOX_7-9</i> <i>For agreement</i>	FR
7.10	UA for a product family containing Chlorocresol PT 2, 3 (BC-RF039183-42) Meeting document: <i>WGI2022_TOX_7-10</i> <i>For agreement</i>	FR
Item 8 - Technical and guidance related issues		Presenter
8.1	Update on guidance development Meeting document: <i>WGI2022_TOX_8-1</i> <i>For discussion</i>	SECR
8.2	Relevant groundwater metabolites Meeting document: <i>WGI2022_TOX_8-2</i> <i>For discussion</i>	SECR
8.3	<i>In situ</i> generated active substances – revision of recommendations Meeting document: <i>WGI2022_TOX_8-3</i> <i>For discussion</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGI2022_TOX_9-1</i> <i>For discussion</i>	SECR
9.2	Interact tool Meeting document: <i>WGI2022_TOX_9-2</i> <i>For discussion</i>	SECR

Environment Working Group		
Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
<u>Including:</u> Interact tool Meeting document: <i>WGI2022_ENV_2</i>		<i>For discussion</i>
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes of WG-IV-2021		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Formic Acid PT2-6 Meeting document: <i>WGI2022_ENV_6-1</i>	BE <i>For agreement</i>
6.2	ED assessment: Reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2) (former MBO) PT2, 6, 11,12,13 Meeting document: <i>WGI2022_ENV_6-2</i>	AT <i>For agreement</i>
6.3	ED assessment: Reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 1:1)" (former HPT) PT 2, 6, 11, 13 Meeting document: <i>WGI2022_ENV_6-3</i>	AT <i>For agreement</i>
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for a product containing active chlorine released from chlorine PT 02, 05 (BC-EQ047299-18) Meeting document: <i>WGI2022_ENV_7-1</i>	SI

7.2	UA for a product containing calcium dihydroxide/calcium hydroxide/caustic lime/hydrated lime/slaked lime PT 02, 03 (BC-JR038510-32) Meeting document: <i>WGI2022_ENV_7-2</i> <i>For agreement</i>	FR
7.3	UA for a product containing calcium oxide/lime/burnt lime/quicklime PT 02, 03 (BC-VJ038509-19) Meeting document: <i>WGI2022_ENV_7-3</i> <i>For agreement</i>	FR
7.4	UA for a product family containing Peracetic acid PT 02, 03, 04 (BC-EW057176-14) Meeting document: <i>WGI2022_ENV_7-4</i> <i>For agreement</i>	BE
7.5	UA for a product family containing Hydrogen peroxide PT 02 (BC-MS029571-20) Meeting document: <i>WGI2022_ENV_7-5</i> <i>For agreement</i>	DE
7.6	UA for a product family containing Hydrogen peroxide PT 02, 04 (BC-UE029056-42) Meeting document: <i>WGI2022_ENV_7-6</i> <i>For agreement</i>	NL
7.7	UA for a product family containing L-(+)-lactic acid PT 03, 04 (BC-XR051157-11) Meeting document: <i>WGI2022_ENV_7-7</i> <i>For agreement</i>	SI
7.8	UA for a product family containing L-(+)-lactic acid PT 02, 03, 04 (BC-HC051278-51) Meeting document: <i>WGI2022_ENV_7-8</i> <i>For agreement</i>	FR
7.9	UA for a product containing 3-iodo-2-propynylbutylcarbamate (IPBC) PT 08 (BC-QN044827-14) Meeting document: <i>WGI2022_ENV_7-9</i> <i>For agreement</i>	DK
7.10	UA for a product family containing Chlorocresol PT 02, 03 (BC-RF039183-42) Meeting document: <i>WGI2022_ENV_7-10</i> <i>For agreement</i>	FR

7.11	Early WG: UA for a product family containing Glutaral PT 06, 11, 12 (BC-AE027041-75) Meeting document: <i>WGI2022_ENV_7-11</i> <i>Scheduled for 21. March 2022</i> <i>For agreement</i>	NL
7.12	Early WG: UA for a product family containing Biphenyl-2-ol - TBC PT 06, 13 (BC-CT032574-27) Meeting document: <i>WGI2022_ENV_7-12</i> <i>For agreement</i>	NL
Item 8 – Technical and guidance related topics		
8.1	In-situ generated active substances: Revision of recommendations – options for assessment of in-situ generated AS Meeting document: <i>WGI2022_ENV_8-1</i> <i>For agreement</i>	SECR
8.2	Disinfection by-products environmental risk assessment Meeting document: <i>WGI2022_ENV_8-2</i> <i>For agreement</i>	FR
8.3	Roadmap for PBT R.11 Guidance update SECR to inform <i>For information</i>	SECR
8.4	Update on Chesar Platform developments SECR to inform <i>For information</i>	SECR
8.5	Proposal for an emission scenario for PT 18 Meeting document: <i>WGI2022_ENV_8-5</i> <i>For agreement</i>	ASO
8.6	PEC/PNEC: concentration of AS as manufactured versus concentration of pure AS Meeting document: <i>WGI2022_ENV_8-6</i> <i>For agreement</i>	ASO
	EG meeting on fate and distribution models Meeting document: <i>WGI2022_ENV_EG_1</i> <i>Schedule for 12. April 2022 - Only relevant for WG members that volunteered to participate in this expert group!</i> <i>For agreement</i>	EG
Item 9 – AOB		
9.1	Other information & lessons learned SECR to inform <i>For information</i>	SECR

Efficacy Working Group		
Chair: Kasia Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-IV-2021		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Formic Acid PT2-6 Meeting document: <i>WGI2022_EFF_6-1</i>	BE <i>For agreement</i>
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for a product containing active chlorine released from chlorine PT 02, 05 (BC-EQ047299-18) Meeting document: <i>WGI2022_EFF_7-1</i>	SI <i>For agreement</i>
7.2	UA for a product containing calcium dihydroxide/calcium hydroxide/caustic lime/hydrated lime/slaked lime PT 02, 03 (BC-JR038510-32) Meeting document: <i>WGI2022_EFF_7-2</i>	FR <i>For agreement</i>
7.3	UA for a product containing calcium oxide/lime/burnt lime/quicklime PT 02, 03 (BC-VJ038509-19) Meeting document: <i>WGI2022_EFF_7-3</i>	FR <i>For agreement</i>
7.4	UA for a product family containing Peracetic acid PT 02, 03, 04 (BC-EW057176-14) Meeting document: <i>WGI2022_EFF_7-4</i>	BE <i>For agreement</i>

7.5	UA for a product family containing Hydrogen peroxide PT 02 (BC-MS029571-20) Meeting document: <i>WGI2022_EFF_7-5</i> <i>For agreement</i>	DE
7.6	UA for a product family containing Hydrogen peroxide PT 02, 04 (BC-UE029056-42) Meeting document: <i>WGI2022_EFF_7-6</i> <i>For agreement</i>	NL
7.7	UA for a product family containing L-(+)-lactic acid PT 03, 04 (BC-XR051157-11) Meeting document: <i>WGI2022_EFF_7-7</i> <i>For agreement</i>	SI
7.8	UA for a product containing 3-iodo-2-propynylbutylcarbamate (IPBC) PT 08 (BC-QN044827-14) Meeting document: <i>WGI2022_EFF_7-8</i> <i>For agreement</i>	DK
7.9	UA for a product family containing L-(+)-lactic acid PT 02, 03, 04 (BC-HC051278-51) Meeting document: <i>WGI2022_EFF_7-9</i> <i>For agreement</i>	FR
7.10	UA for a product family containing Chlorocresol PT 02, 03 (BC-RF039183-42) Meeting document: <i>WGI2022_EFF_7-10</i> <i>For agreement</i>	FR
Item 8 - Technical and guidance related issues		
8.1	Efficacy testing for disinfectants at elevated use temperatures Meeting document: <i>WGI2022_EFF_8-1</i>	DE
Item 9 – AOB		
9.1	Other information Meeting document: <i>WGI2022_EFF_9-1</i> <i>For information</i>	ECHA
9.2	Interact tool Meeting document: <i>WGI2022_EFF_9-2</i> <i>For discussion</i>	ECHA